UBS has initiated a leadership transition within its O’Connor unit after the co-heads of the capital solutions strategy, Rodrigo Trelles and Baxter Wasson, declined offers to join Cantor Fitzgerald. According to a source familiar with the matter who spoke to Reuters, both executives opted not to move to the U.S. brokerage despite earlier expectations tied to Cantor’s planned acquisition of O’Connor.
In their place, UBS O’Connor has appointed Gregory Najarian as portfolio manager, effective immediately. Najarian will lead the team with support from Jaeho Choi and Joshua Mercado, signaling UBS’s efforts to maintain stability within the capital solutions business during a broader strategic shift. Bloomberg News was the first to report the developments.
The transition follows a challenging period for UBS. Earlier this month, the Swiss banking group confirmed it would wind down certain investment funds operated by O’Connor after losses linked to exposure to First Brands Group, a U.S. auto parts supplier that recently filed for bankruptcy. The decision highlights UBS’s ongoing effort to streamline its operations and reduce risk across its alternative investment portfolio.
O’Connor, a long-standing alternatives platform under UBS, spans hedge funds, alternative credit, and commodities strategies. Despite the restructuring, UBS continues to position the platform as an important part of its broader investment offering.
Cantor Fitzgerald, meanwhile, had reached an agreement earlier this year to acquire O’Connor as part of its own expansion into alternative investments. The move was seen as a strategic step for Cantor, while UBS has been reshaping its business following the landmark merger with Credit Suisse in 2023.
The leadership changes and fund wind-downs reflect a period of transition for UBS as it refocuses on core priorities, manages legacy risks, and prepares for the next phase of integration and consolidation post-merger.


Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Washington Post Publisher Will Lewis Steps Down After Layoffs
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Instagram Outage Disrupts Thousands of U.S. Users
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



